These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 30572795

  • 1. Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.
    Hwang A, Iskandar A, Dasanu CA.
    J Oncol Pharm Pract; 2019 Sep; 25(6):1531-1533. PubMed ID: 30572795
    [Abstract] [Full Text] [Related]

  • 2. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y.
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [Abstract] [Full Text] [Related]

  • 3. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K, Naruse I, Shimizu K, Asao T.
    J Cancer Res Ther; 2020 Oct; 16(4):919-921. PubMed ID: 32930141
    [Abstract] [Full Text] [Related]

  • 4. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
    Nitawaki T, Sakata Y, Kawamura K, Ichikado K.
    BMC Pulm Med; 2017 Dec 06; 17(1):173. PubMed ID: 29207989
    [Abstract] [Full Text] [Related]

  • 5. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
    Ikeda S, Yoshioka H, Arita M, Sakai T, Sone N, Nishiyama A, Niwa T, Hotta M, Tanaka T, Ishida T.
    Jpn J Clin Oncol; 2015 Feb 06; 45(2):221-4. PubMed ID: 25398579
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
    Kashizaki F, Tanaka A, Sekido Y.
    J Med Case Rep; 2022 Aug 24; 16(1):316. PubMed ID: 35999557
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators.
    N Engl J Med; 2017 Aug 31; 377(9):829-838. PubMed ID: 28586279
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM.
    Future Oncol; 2018 Aug 31; 14(18):1875-1882. PubMed ID: 29536761
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
    Yoneshima Y, Okamoto I, Takano T, Enokizu A, Iwama E, Harada T, Takayama K, Nakanishi Y.
    Lung Cancer; 2015 Jun 31; 88(3):349-51. PubMed ID: 25837798
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
    Ramachandran P, Morcus R, Tahir M, Onukogu I, Spinowitz B, Wang JC.
    J Med Case Rep; 2018 Oct 19; 12(1):303. PubMed ID: 30336782
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.